ImageneBio (IMA) EBITDA (2020 - 2025)

ImageneBio has disclosed EBITDA across 6 years of filings, most recently posting -$26.6 million for Q3 2025.

• In Q3 2025, EBITDA fell 1206.19% year-over-year to -$26.6 million; the TTM figure through Sep 2025 stood at -$68.1 million (down 17.36% YoY), while the FY2024 annual figure was -$59.0 million, up 21.8% from the prior year.
• EBITDA came in at -$26.6 million for Q3 2025 at ImageneBio, down from -$7.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.8 million in Q4 2021 to a low of -$28.1 million in Q4 2024.
• Average EBITDA over 5 years is -$15.0 million, with a median of -$15.8 million recorded in 2024.
• Year-over-year, EBITDA soared 110.72% in 2021 and sank 1206.19% in 2025.
• Over 5 years, EBITDA stood at $2.8 million in 2021, then sank by 641.33% to -$15.1 million in 2022, then tumbled by 44.95% to -$21.9 million in 2023, then dropped by 28.33% to -$28.1 million in 2024, then grew by 5.41% to -$26.6 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$26.6 million in Q3 2025, -$7.4 million in Q2 2025, and -$6.0 million in Q1 2025.